Vimarsana
Biggest News Aggregation in the World

Page 17 - Double Blind Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Double Blind Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Double Blind Study Today - Breaking & Trending Today

Topical Vs Oral Minoxidil for AGA: Which Is More Effective? - Vimarsana News

Topical Vs Oral Minoxidil for AGA: Which Is More Effective?

Efficacy and safety of the two formulations were directly compared in a randomized, controlled, double-blind study of men with AGA conducted in Brazil.

More Adults Are Participating in Cancer Clinical Trials - Vimarsana News

More Adults Are Participating in Cancer Clinical Trials

New estimates suggest that more adults with cancer are participating in cancer trial research, especially at National Cancer Institute–designated centers, but overall enrollment rates remain low.

AUD Meds at Discharge Dramatically Cuts Rehospitalization - Vimarsana News

AUD Meds at Discharge Dramatically Cuts Rehospitalization

Prescribing medication for alcohol use disorder on hospital discharge was associated with a significant decrease in the risk for an alcohol-related rehospitalization.

Can Short Cycles of a Fasting-Like Diet Reduce Disease Risk? - Vimarsana News

Can Short Cycles of a Fasting-Like Diet Reduce Disease Risk?

Monthly cycles of a 5-day FMD (plant-based, low-calorie, and low-protein) followed by a normal diet appeared to improve markers of prediabetes and immune system aging.

Hidradenitis Suppurativa: Sonelokimab Shows Promise in Study - Vimarsana News

Hidradenitis Suppurativa: Sonelokimab Shows Promise in Study

Sonelokimab is a novel humanized nanobody that selectively binds to interleukin (IL)-17A and IL-17F.